Hydroxysafflor yellow A inhibited lipopolysaccharide‐induced non‐small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways
Open Access
- 4 May 2019
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 10 (6) , 1319-1333
Abstract
Background: Chronic inflammation plays a significant role in the occurrence and development of non‐small cell lung cancer (NSCLC). Hydroxysafflor yellow A (HSYA), a chemical compound of the yellow color pigments extracted from the safflower, has been widely used in clinical treatment with positive antioxidation, anti‐inflammation, and antitumor effects. However, the role and underlying mechanisms of HYSA on development and progress in inflammation‐mediated NSCLC are unknown.Methods: Cell counting kit‐8, colony formation, EdU, cell apoptosis, wound healing, Transwell migration and invasion, and enzyme‐linked immunosorbent assays; flow cytometry; and Western blotting were conducted using human NSCLC cell lines A549 and H1299.Results: Lipopolysaccharide (LPS) significantly promoted the proliferation and enhanced colony formation of A549 and H1299 cells, while HYSA notably reversed the effects of LPS. HYSA induced apoptosis of LPS‐mediated A549 and H1299 cells in a dose dependent manner; and remarkably suppressed migration, invasion, and epithelial–mesenchymal transition (EMT), significantly regulated production of LPS‐induced inflammation cytokines, and downregulated protein expression of PI3K/Akt/mTOR and ERK/MAPK signaling pathways in LPS‐induced A549 and H1299 cells. Furthermore, PI3K (LY294002) and ERK (SCH772984) inhibitors remarkably inhibited proliferation, migration, invasion, and EMT, and induced apoptosis in LPS‐mediated A549 and H1299 cells. These effects were even more obvious in the presence of HYSA and LY294002 or SCH772984 compared to those of either agent alone.Conclusion: HYSA suppressed LPS‐mediated proliferation, migration, invasion, and EMT in A549 and H1299 cells by inhibiting the PI3K/Akt/mTOR and ERK/MAPK signaling pathways, indicating that HYSA may be a potential candidate to treat inflammation‐mediated NSCLC.Keywords
This publication has 62 references indexed in Scilit:
- Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activationCancer Immunology, Immunotherapy, 2012
- Growth factors in tumor microenvironmentFrontiers in Bioscience-Landmark, 2010
- Molecular networks for the study of TCM PharmacologyBriefings in Bioinformatics, 2009
- Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Natural products and drug discoveryEMBO Reports, 2009
- Cancer and the tumor microenvironment: a review of an essential relationshipCancer Chemotherapy and Pharmacology, 2008
- Cancer-related inflammationNature, 2008
- Drug resistance, predictive markers and pharmacogenomics in colorectal cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006
- Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosisLung Cancer, 2006
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002